Waverley Pharma Inc.
WAVE.V
TSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -28.20% | 2.20% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -28.20% | 2.20% | |||
| Cost of Revenue | 3.09% | -15.97% | |||
| Gross Profit | -62.45% | 34.11% | |||
| SG&A Expenses | 42.32% | 11.01% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 24.18% | -5.24% | |||
| Operating Income | -1,947.30% | 154.01% | |||
| Income Before Tax | -753.73% | 19.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -759.70% | 19.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -759.70% | 19.92% | |||
| EBIT | -1,947.30% | 154.01% | |||
| EBITDA | -646.19% | 1,758.33% | |||
| EPS Basic | -700.00% | 20.00% | |||
| Normalized Basic EPS | -900.00% | 33.33% | |||
| EPS Diluted | -700.00% | 20.00% | |||
| Normalized Diluted EPS | -900.00% | 33.33% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||